Dr. Grivas on Comparisons Between ATM and BRCA1/2 Mutations in mCRPC

Petros Grivas, MD
Published: Wednesday, Feb 26, 2020



Petros Grivas, MD, medical oncologist, Seattle Cancer Care Alliance, associate professor, University of Washington and Fred Hutchinson Cancer Center, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer (mCRPC).

ATM and BRCA1/2 genes have been identified in patients with prostate cancer. When looking at the totality of patients with mCRPC, approximately 12% have germline mutations and 25% of all patients with prostate cancer have somatic mutations, said Grivas.

In the PROfound trial, there was significant activity of olaparib (Lynparza) in selected patients with BRCA1/2 and ATM mutations; the majority of benefit was in patients with BRCA2 mutations. However, there were questions about the benefit in patients with ATM mutations. In this study, it was shown that the response to standard therapies appears compatible with patients who have germline BRCA and ATM mutations compared with those who do not have germline mutations. The germline BRCA1/2 mutations did not appear to impact a response to standard therapies in a metastatic castration-resistant setting, concludes Grivas.
SELECTED
LANGUAGE


Petros Grivas, MD, medical oncologist, Seattle Cancer Care Alliance, associate professor, University of Washington and Fred Hutchinson Cancer Center, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer (mCRPC).

ATM and BRCA1/2 genes have been identified in patients with prostate cancer. When looking at the totality of patients with mCRPC, approximately 12% have germline mutations and 25% of all patients with prostate cancer have somatic mutations, said Grivas.

In the PROfound trial, there was significant activity of olaparib (Lynparza) in selected patients with BRCA1/2 and ATM mutations; the majority of benefit was in patients with BRCA2 mutations. However, there were questions about the benefit in patients with ATM mutations. In this study, it was shown that the response to standard therapies appears compatible with patients who have germline BRCA and ATM mutations compared with those who do not have germline mutations. The germline BRCA1/2 mutations did not appear to impact a response to standard therapies in a metastatic castration-resistant setting, concludes Grivas.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x